Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.

Trial Details

NCT ID
NCT06050317
Phase
PHASE2
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Sintilimab Plus mFFN or NALIRIFOX and Radiation
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • ECOG PS 0-1
  • Pathological tissue-confirmed unresectable locally advanced pancreatic cancer
  • Pancreatic cancer patients who have not received systemic anti-tumor therapy
  • Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →